share_log

四環醫藥：截至二零二四年三月三十一日止之股份發行人的證券變動月報表

SIHUAN PHARM: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

香港交易所 ·  Apr 2 04:04
Summary by Moomoo AI
四環醫藥（00460.HK）於2024年4月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份變動情況。報告顯示，四環醫藥的法定/註冊股本及已發行股份在本月內均無變動，維持在1,000,000,000港元及9,329,999,206股。此外，根據2017年10月24日採納的股份期權計劃，公司本月底結存的股份期權數目為74,110,000股，並無新增股份期權發行。四環醫藥確認，所有證券變動均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
四環醫藥（00460.HK）於2024年4月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年3月31日的公司股份變動情況。報告顯示，四環醫藥的法定/註冊股本及已發行股份在本月內均無變動，維持在1,000,000,000港元及9,329,999,206股。此外，根據2017年10月24日採納的股份期權計劃，公司本月底結存的股份期權數目為74,110,000股，並無新增股份期權發行。四環醫藥確認，所有證券變動均已獲得董事會批准，並符合香港聯合交易所有限公司證券上市規則的相關要求。
Four Circle Pharmaceuticals (00460.HK) filed with Hong Kong Trading and Settlement Limited on April 2, 2024 with Hong Kong Trading and Settlement Limited, reporting changes in company shares for the year ended March 31, 2024. The report showed that the Regulated/Registered Share Capital and Issued Shares of Four Circles Pharmaceuticals remained unchanged during the month, at HK$1,000,000,000 and 9,329,999,206 shares. In addition, under the share option plan adopted on October 24, 2017, the Company had 74,110,000 shares outstanding at the end of this month and no additional share options were issued. Fourring Pharmaceuticals confirms that all securities movements have been approved by the Board of Directors and comply with the relevant requirements of the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited.
Four Circle Pharmaceuticals (00460.HK) filed with Hong Kong Trading and Settlement Limited on April 2, 2024 with Hong Kong Trading and Settlement Limited, reporting changes in company shares for the year ended March 31, 2024. The report showed that the Regulated/Registered Share Capital and Issued Shares of Four Circles Pharmaceuticals remained unchanged during the month, at HK$1,000,000,000 and 9,329,999,206 shares. In addition, under the share option plan adopted on October 24, 2017, the Company had 74,110,000 shares outstanding at the end of this month and no additional share options were issued. Fourring Pharmaceuticals confirms that all securities movements have been approved by the Board of Directors and comply with the relevant requirements of the Listing Rules of the Stock Exchange of Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more